1 April 2024 v2025.41.1 limited_company_frs_102_section_1a_v1_1_2 companies_houseSoftwarefalsetruetruetrueNo description of principal activityfalsetruexbrli:purexbrli:sharesiso4217:GBP080411292024-04-012025-03-31080411292025-03-31080411292024-03-3108041129core:WithinOneYear2025-03-3108041129core:WithinOneYear2024-03-3108041129core:ShareCapital2025-03-3108041129core:ShareCapital2024-03-3108041129core:RetainedEarningsAccumulatedLosses2025-03-3108041129core:RetainedEarningsAccumulatedLosses2024-03-3108041129bus:Director12024-04-012025-03-3108041129bus:RegisteredOffice2024-04-012025-03-3108041129core:NetGoodwill2024-04-012025-03-3108041129core:Goodwill2024-04-012025-03-3108041129core:PlantMachinery2024-04-012025-03-3108041129core:OfficeEquipment2024-04-012025-03-31080411292023-04-012024-03-3108041129core:NetGoodwill2025-03-3108041129core:PlantMachinery2024-04-0108041129core:PlantMachinery2025-03-3108041129core:PlantMachinery2024-03-3108041129core:CostValuation2024-04-0108041129core:AdditionsToInvestments2025-03-3108041129core:DisposalsRepaymentsInvestments2025-03-3108041129core:ProvisionsForImpairmentInvestments2024-04-0108041129core:ImpairmentLossProvisionsForImpairmentInvestments2025-03-310804112912024-04-012025-03-3108041129countries:EnglandWales2024-04-012025-03-3108041129bus:AuditExemptWithAccountantsReport2024-04-012025-03-3108041129bus:PrivateLimitedCompanyLtd2024-04-012025-03-3108041129bus:SmallEntities2024-04-012025-03-3108041129bus:FullAccounts2024-04-012025-03-31
Company registration number:
08041129
Histology Equipment Services Ltd.
Unaudited Filleted Financial Statements for the year ended
31 March 2025
Histology Equipment Services Ltd.
Chartered accountant's report to the board of directors on the preparation of the unaudited statutory financial statements of Histology Equipment Services Ltd.
Year ended
31 March 2025
In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the
financial statements
of
Histology Equipment Services Ltd.
for the year ended
31 March 2025
which comprise the income statement, statement of income and retained earnings, statement of financial position and related notes from the company’s accounting records and from information and explanations you have given us.
As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at icaew.com/​regulations.
This report is made solely to the Board of Directors of
Histology Equipment Services Ltd.
, as a body, in accordance with the terms of our engagement letter dated 14 July 2021. Our work has been undertaken solely to prepare for your approval the
financial statements
of
Histology Equipment Services Ltd.
and state those matters that we have agreed to state to the Board of Directors of
Histology Equipment Services Ltd.
, as a body, in this report in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than
Histology Equipment Services Ltd.
and its Board of Directors, as a body, for our work or for this report.
It is your duty to ensure that
Histology Equipment Services Ltd.
has kept adequate accounting records and to prepare statutory
financial statements
that give a true and fair view of the assets, liabilities, financial position and profit of
Histology Equipment Services Ltd.
. You consider that
Histology Equipment Services Ltd.
is exempt from the statutory audit requirement for the year.
We have not been instructed to carry out an audit or a review of the financial statements of Histology Equipment Services Ltd.. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.
A&C Chartered Accountants
Marsland Chambers
1a Marsland Road
Sale Moor
Cheshire
M33 3HP
United Kingdom
Histology Equipment Services Ltd.
Statement of Financial Position
31 March 2025
20252024
Note££
Fixed assets    
Tangible assets 6
11,584
 
12,410
 
Investments 7 -  
383,807
 
11,584
 
396,217
 
Current assets    
Stocks
2,228
 
4,538
 
Debtors 8
117,368
 
142,104
 
Cash at bank and in hand
648,511
 
240,810
 
768,107
 
387,452
 
Creditors: amounts falling due within one year 9
(52,381
)
(93,751
)
Net current assets
715,726
 
293,701
 
Total assets less current liabilities 727,310   689,918  
Provisions for liabilities
(2,895
)
(3,102
)
Net assets
724,415
 
686,816
 
Capital and reserves    
Called up share capital
1
 
1
 
Profit and loss account
724,414
 
686,815
 
Shareholders funds
724,415
 
686,816
 
For the year ending
31 March 2025
, the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Director's responsibilities:
  • The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476;
  • The director acknowledges their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
These
financial statements
have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies’ regime.
In accordance with Section 444 of the Companies Act 2006, the income statement has not been delivered.
These
financial statements
were approved by the board of directors and authorised for issue on
25 June 2025
, and are signed on behalf of the board by:
V Niles
Director
Company registration number:
08041129
Histology Equipment Services Ltd.
Notes to the Financial Statements
Year ended
31 March 2025

1 General information

The company is a private company limited by shares and is registered in England and Wales. The address of the registered office is
113 Framingham Road
,
Sale
,
Cheshire
,
M33 3RL
, .

2 Statement of compliance

These
financial statements
have been prepared in compliance with FRS 102 Section 1A, 'The Financial Reporting Standard applicable to the UK and Republic of Ireland'.

3 Accounting policies

Basis of preparation

The
financial statements
have been prepared on the historical cost basis, as modified by the revaluation of certain assets.
The
financial statements
are prepared in sterling, which is the functional currency of the company.

Turnover

Turnover is measured at the fair value of the consideration received or receivable for goods supplied, net of discounts and Value Added Tax.
Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer, usually on despatch of the goods; the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

Current tax

Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

Goodwill

Purchased goodwill arises on business acquisitions and represents the difference between the cost of acquisition and the fair values of the identifiable assets and liabilities acquired.
Goodwill is initially recorded at cost, and is subsequently stated at cost less any accumulated amortisation and accumulated impairment losses. It is amortised on a straight-line basis over the useful economic life of the asset. Where a reliable estimate of the useful life of goodwill cannot be made, the life is presumed not to exceed five years.

Intangible assets

Intangible assets are initially measured at cost and are subsequently measured at cost less any accumulated amortisation and accumulated impairment losses or at a revalued amount. However, Intangible assets acquired as part of a business combination are only recognised separately from goodwill when they arise from contractual or other legal rights, are separable, the expected future economic benefits are probable and the cost or value can be measured reliably.
Any intangible assets carried at a revalued amount are recorded at the fair value at the date of revaluation, as determined by reference to an active market, less any subsequent accumulated amortisation and subsequent accumulated impairment losses.
An increase in the carrying amount of an asset as a result of a revaluation is recognised in other comprehensive income and accumulated in capital and reserves. However, the increase is recognised in profit or loss to the extent that it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in capital and reserves. If a revaluation decrease exceeds the accumulated revaluation gains accumulated in capital and reserves in respect of that asset, the excess is recognised in profit or loss.
Amortisation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful economic life of that asset as follows:
Goodwill
10% Straight Line

Tangible assets

Tangible assets are initially measured at cost, and are subsequently measured at cost less any accumulated depreciation and accumulated impairment losses or at a revalued amount.
Any tangible assets carried at a revalued amount are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses.
An increase in the carrying amount of an asset as a result of a revaluation is recognised in other comprehensive income and accumulated in capital and reserves. However, the increase is recognised in profit or loss to the extent that it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in capital and reserves. If a revaluation decrease exceeds the accumulated revaluation gains accumulated in capital and reserves in respect of that asset, the excess is recognised in profit or loss.
Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful economic life of that asset as follows:
Plant and machinery
15% Reducing Balance
Office equipment
15% Reducing Balance

Fixed asset investments

Investments in subsidiaries, associates and joint ventures accounted for in accordance with the cost model are recorded at cost less any accumulated impairment losses.
Investments in subsidiaries, associates and joint ventures accounted for in accordance with the fair value model are initially recorded at the transaction price. At each reporting date, the investments are measured at fair value, with changes in fair value recognised in other comprehensive income or profit or loss. Where it is impracticable to measure fair value reliably without undue cost or effort, the cost model will be adopted.
Dividends and other distributions received from the investment are recognised as income without regard to whether the distributions are from accumulated profits of the associate arising before or after the date of acquisition.
Other fixed asset investments which are listed are measured at fair value with changes in fair value being recognised in profit or loss.
All other Investments held as fixed assets are initially recorded at cost, and are subsequently stated at cost less any accumulated impairment losses.

Stocks

Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost includes all costs of purchase, costs of conversion and other costs incurred in bringing the stocks to their present location and condition.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is more likely than not that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured on an undiscounted basis at the tax rates that would apply in the periods in which timing differences are expected to reverse, based on tax rates and laws enacted at the statement of financial position date.

Provisions for liabilities

Provisions are recognised when the entity has an obligation at the reporting date as a result of a past event; it is probable that the entity will be required to transfer economic benefits in settlement and the amount of the obligation can be estimated reliably. Provisions are recognised as a liability in the statement of financial position and the amount of the provision as an expense.
Provisions are initially measured at the best estimate of the amount required to settle the obligation at the reporting date and subsequently reviewed at each reporting date and adjusted to reflect the current best estimate of the amount that would be required to settle the obligation. Any adjustments to the amounts previously recognised are recognised in profit or loss unless the provision was originally recognised as part of the cost of an asset. When a provision is measured at the present value of the amount expected to be required to settle the obligation, the unwinding of the discount is recognised in finance costs in profit or loss in the period it arises.

Defined contribution pension plan

Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided. Prepaid contributions are recognised as an asset to the extent that the prepayment will lead to a reduction in future payments or a cash refund.

4 Average number of employees

The average number of persons employed by the company during the year was
2
(2024:
2.00
).

5 Intangible assets

Goodwill
£
Cost  
At
1 April 2024
and
31 March 2025
75,000
 
Amortisation  
At
1 April 2024
and
31 March 2025
75,000
 
Carrying amount  
At
31 March 2025
-  
At 31 March 2024 -  

6 Tangible assets

Plant and machinery etc.
£
Cost  
At
1 April 2024
36,991
 
Additions
1,689
 
Disposals
(3,000
)
At
31 March 2025
35,680
 
Depreciation  
At
1 April 2024
24,581
 
Charge
1,202
 
Disposals
(1,687
)
At
31 March 2025
24,096
 
Carrying amount  
At
31 March 2025
11,584
 
At 31 March 2024
12,410
 

7 Investments

Other investments other than loans
£
Cost  
At
1 April 2024
360,213
 
Additions
67,817
 
Disposals
(428,030
)
At
31 March 2025
-  
Impairment  
At
1 April 2024
(23,594
)
Impairment losses
23,594
 
At
31 March 2025
-  
Carrying amount  
At
31 March 2025
-  
At 31 March 2024
383,807
 
The significant assumptions underlying the valuation models and techniques used to determine the fair values of the investment assets were the open market rates at the balance sheet date.

8 Debtors

20252024
££
Trade debtors
96,406
 
136,971
 
Other debtors
20,962
 
5,133
 
117,368
 
142,104
 

9 Creditors: amounts falling due within one year

20252024
££
Taxation and social security
50,477
 
72,707
 
Other creditors
1,904
 
21,044
 
52,381
 
93,751
 

10 Director's advances, credit and guarantees

The following advances and credits to director V Niles subsisted during the year ended 31 March 2024 and the year ended 31 March 2025:
Year ended 31 March 2024
Balance at 01/04/2023: £17,217 owed to the director.
£2,018 was loaned to the company in the year.
Balance at 31/03/2024: £19,235 owed to the director.
Year ended 31 March 2025:
Balance at 01/04/2024: £19,235 owed to the director.
£19,140 was loaned to the director in the year.
Balance at 31/03/2025: £95 owed to the director.
The above loan is unsecured, interest free and repayable on demand.

11 Controlling party

During the year ended 31 March 2025, V Niles controlled the company by virtue of a controlling interest of 100% of the issued ordinary share capital.